KR20230127254A - 치환된 거대고리 화합물 및 관련 치료방법 - Google Patents

Info

Publication number

KR20230127254A

KR20230127254A KR1020237024587A KR20237024587A KR20230127254A KR 20230127254 A KR20230127254 A KR 20230127254A KR 1020237024587 A KR1020237024587 A KR 1020237024587A KR 20237024587 A KR20237024587 A KR 20237024587A KR 20230127254 A KR20230127254 A KR 20230127254A

Authority

KR

South Korea

Prior art keywords

formula

another embodiment

ring

alkyl

alkylene

Prior art date

2020-12-21

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 150000002678 macrocyclic compounds Chemical class 0.000 title description 4
• 238000002560 therapeutic procedure Methods 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims abstract description 203
• 238000000034 method Methods 0.000 claims abstract description 37
• 201000003631 narcolepsy Diseases 0.000 claims abstract description 30
• 238000011282 treatment Methods 0.000 claims abstract description 20
• 208000001573 Cataplexy Diseases 0.000 claims abstract description 17
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
• 229910052736 halogen Inorganic materials 0.000 claims description 235
• 150000002367 halogens Chemical group 0.000 claims description 235
• 239000000203 mixture Substances 0.000 claims description 210
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 185
• 125000000623 heterocyclic group Chemical group 0.000 claims description 183
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 158
• 125000003118 aryl group Chemical group 0.000 claims description 141
• 150000003839 salts Chemical class 0.000 claims description 109
• 229910052739 hydrogen Inorganic materials 0.000 claims description 92
• 125000004076 pyridyl group Chemical group 0.000 claims description 89
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 88
• 229910052805 deuterium Inorganic materials 0.000 claims description 88
• 125000003373 pyrazinyl group Chemical group 0.000 claims description 80
• 125000002098 pyridazinyl group Chemical group 0.000 claims description 80
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 80
• 125000004306 triazinyl group Chemical group 0.000 claims description 80
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 75
• 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 67
• 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 48
• 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 48
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 38
• 125000001072 heteroaryl group Chemical group 0.000 claims description 34
• 229910052799 carbon Inorganic materials 0.000 claims description 33
• 150000001721 carbon Chemical group 0.000 claims description 31
• 239000003814 drug Substances 0.000 claims description 23
• 125000000217 alkyl group Chemical group 0.000 claims description 20
• 239000003937 drug carrier Substances 0.000 claims description 11
• 229940079593 drug Drugs 0.000 claims description 7
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
• 238000004519 manufacturing process Methods 0.000 claims description 3
• 206010010904 Convulsion Diseases 0.000 claims 1
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 128
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 92
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 90
• 239000000243 solution Substances 0.000 description 85
• 238000000132 electrospray ionisation Methods 0.000 description 84
• 230000002829 reductive effect Effects 0.000 description 76
• 239000012299 nitrogen atmosphere Substances 0.000 description 72
• 239000007787 solid Substances 0.000 description 72
• 229910052760 oxygen Inorganic materials 0.000 description 55
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
• 238000003818 flash chromatography Methods 0.000 description 44
• -1 organic acid salts Chemical class 0.000 description 43
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 42
• 239000000706 filtrate Substances 0.000 description 41
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 40
• 230000002441 reversible effect Effects 0.000 description 39
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 37
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 36
• 238000005481 NMR spectroscopy Methods 0.000 description 35
• 235000019439 ethyl acetate Nutrition 0.000 description 33
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 33
• 239000012043 crude product Substances 0.000 description 31
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
• 239000003921 oil Substances 0.000 description 30
• 235000019198 oils Nutrition 0.000 description 30
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 29
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
• 239000012044 organic layer Substances 0.000 description 28
• 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 27
• 238000006243 chemical reaction Methods 0.000 description 26
• 238000001914 filtration Methods 0.000 description 26
• 239000011734 sodium Substances 0.000 description 26
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 25
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 23
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 22
• 239000001257 hydrogen Substances 0.000 description 22
• 239000012267 brine Substances 0.000 description 21
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 21
• 239000000460 chlorine Substances 0.000 description 20
• 230000000694 effects Effects 0.000 description 20
• 238000010898 silica gel chromatography Methods 0.000 description 20
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 18
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 17
• 208000008589 Obesity Diseases 0.000 description 17
• 235000020824 obesity Nutrition 0.000 description 17
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
• HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 16
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
• 206010041349 Somnolence Diseases 0.000 description 15
• 201000010099 disease Diseases 0.000 description 15
• 239000012258 stirred mixture Substances 0.000 description 15
• 238000005160 1H NMR spectroscopy Methods 0.000 description 14
• 210000004027 cell Anatomy 0.000 description 14
• 102000005962 receptors Human genes 0.000 description 14
• 108020003175 receptors Proteins 0.000 description 14
• 229940124597 therapeutic agent Drugs 0.000 description 14
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 13
• 239000012298 atmosphere Substances 0.000 description 13
• 208000035475 disorder Diseases 0.000 description 13
• 206010020765 hypersomnia Diseases 0.000 description 13
• 230000000069 prophylactic effect Effects 0.000 description 13
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 12
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• 229910052731 fluorine Inorganic materials 0.000 description 12
• 239000011737 fluorine Substances 0.000 description 12
• 229910052720 vanadium Inorganic materials 0.000 description 12
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
• 238000011534 incubation Methods 0.000 description 11
• 208000011580 syndromic disease Diseases 0.000 description 11
• GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 10
• 102000002512 Orexin Human genes 0.000 description 9
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
• 108060005714 orexin Proteins 0.000 description 9
• 229920006395 saturated elastomer Polymers 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• 208000018737 Parkinson disease Diseases 0.000 description 8
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
• 238000009472 formulation Methods 0.000 description 8
• RHLMXWCISNJNDH-UHFFFAOYSA-N n-[2-[3-[[5-[3-(dimethylcarbamoyl)phenyl]-2-methoxyphenyl]sulfonylamino]anilino]ethyl]-3-methylbenzamide Chemical compound COC1=CC=C(C=2C=C(C=CC=2)C(=O)N(C)C)C=C1S(=O)(=O)NC(C=1)=CC=CC=1NCCNC(=O)C1=CC=CC(C)=C1 RHLMXWCISNJNDH-UHFFFAOYSA-N 0.000 description 8
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
• 239000011541 reaction mixture Substances 0.000 description 8
• 238000003756 stirring Methods 0.000 description 8
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 7
• KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 7
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 7
• 239000000556 agonist Substances 0.000 description 7
• 125000004429 atom Chemical group 0.000 description 7
• 239000000872 buffer Substances 0.000 description 7
• 230000035699 permeability Effects 0.000 description 7
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 7
• DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 7
• 238000000746 purification Methods 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 238000012360 testing method Methods 0.000 description 7
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
• 239000007821 HATU Substances 0.000 description 6
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
• 230000004913 activation Effects 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• WMSPXQIQBQAWLL-UHFFFAOYSA-N cyclopropanesulfonamide Chemical compound NS(=O)(=O)C1CC1 WMSPXQIQBQAWLL-UHFFFAOYSA-N 0.000 description 6
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 6
• 231100000252 nontoxic Toxicity 0.000 description 6
• 230000003000 nontoxic effect Effects 0.000 description 6
• 239000003208 petroleum Substances 0.000 description 6
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
• 238000002953 preparative HPLC Methods 0.000 description 6
• 208000019116 sleep disease Diseases 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 6
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 5
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
• 125000006163 5-membered heteroaryl group Chemical group 0.000 description 5
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
• 239000012981 Hank's balanced salt solution Substances 0.000 description 5
• 208000016588 Idiopathic hypersomnia Diseases 0.000 description 5
• 206010028980 Neoplasm Diseases 0.000 description 5
• 241000700159 Rattus Species 0.000 description 5
• 125000002393 azetidinyl group Chemical group 0.000 description 5
• 201000011510 cancer Diseases 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 210000003494 hepatocyte Anatomy 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 125000002757 morpholinyl group Chemical group 0.000 description 5
• 210000002569 neuron Anatomy 0.000 description 5
• 125000003566 oxetanyl group Chemical group 0.000 description 5
• 239000000546 pharmaceutical excipient Substances 0.000 description 5
• 208000022925 sleep disturbance Diseases 0.000 description 5
• 229910000104 sodium hydride Inorganic materials 0.000 description 5
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
• 206010010071 Coma Diseases 0.000 description 4
• 206010019280 Heart failures Diseases 0.000 description 4
• 108050000742 Orexin Receptor Proteins 0.000 description 4
• 102000008834 Orexin receptor Human genes 0.000 description 4
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 125000004432 carbon atom Chemical group C* 0.000 description 4
• 229910052801 chlorine Inorganic materials 0.000 description 4
• 125000000753 cycloalkyl group Chemical group 0.000 description 4
• NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 4
• PFWWSGFPICCWGU-UHFFFAOYSA-N cyclopropanesulfonyl chloride Chemical compound ClS(=O)(=O)C1CC1 PFWWSGFPICCWGU-UHFFFAOYSA-N 0.000 description 4
• NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
• 125000000532 dioxanyl group Chemical group 0.000 description 4
• 235000019441 ethanol Nutrition 0.000 description 4
• 206010016256 fatigue Diseases 0.000 description 4
• 239000012065 filter cake Substances 0.000 description 4
• 125000000524 functional group Chemical group 0.000 description 4
• KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• DRINJBFRTLBHNF-UHFFFAOYSA-N propane-2-sulfonyl chloride Chemical compound CC(C)S(Cl)(=O)=O DRINJBFRTLBHNF-UHFFFAOYSA-N 0.000 description 4
• 230000007958 sleep Effects 0.000 description 4
• 125000001424 substituent group Chemical group 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
• 229910052721 tungsten Inorganic materials 0.000 description 4
• KATUJIBGOQRZAH-UHFFFAOYSA-N 3-bromo-2-(1,4-dioxaspiro[4.5]decan-8-yloxymethyl)pyridine Chemical compound BrC1=C(COC(CC2)CCC22OCCO2)N=CC=C1 KATUJIBGOQRZAH-UHFFFAOYSA-N 0.000 description 3
• 208000024827 Alzheimer disease Diseases 0.000 description 3
• 206010002091 Anaesthesia Diseases 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 208000031773 Insulin resistance syndrome Diseases 0.000 description 3
• 239000012839 Krebs-Henseleit buffer Substances 0.000 description 3
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 3
• 208000012902 Nervous system disease Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 208000030886 Traumatic Brain injury Diseases 0.000 description 3
• INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 3
• 230000037005 anaesthesia Effects 0.000 description 3
• 230000037007 arousal Effects 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
• 210000003169 central nervous system Anatomy 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• 238000004296 chiral HPLC Methods 0.000 description 3
• 230000001054 cortical effect Effects 0.000 description 3
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
• GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 3
• 239000008298 dragée Substances 0.000 description 3
• 238000000537 electroencephalography Methods 0.000 description 3
• 238000002567 electromyography Methods 0.000 description 3
• 150000002430 hydrocarbons Chemical class 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 3
• 208000001797 obstructive sleep apnea Diseases 0.000 description 3
• 239000012074 organic phase Substances 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 3
• SJMCLWCCNYAWRQ-UHFFFAOYSA-N propane-2-sulfonamide Chemical compound CC(C)S(N)(=O)=O SJMCLWCCNYAWRQ-UHFFFAOYSA-N 0.000 description 3
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 208000020016 psychiatric disease Diseases 0.000 description 3
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 201000002859 sleep apnea Diseases 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
• 230000009529 traumatic brain injury Effects 0.000 description 3
• FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 3
• IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 2
• SVSSZFBZFUSINI-HTQZYQBOSA-N 1-O-tert-butyl 2-O-methyl (2R,3R)-3-hydroxypyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)[C@H]1[C@H](O)CCN1C(=O)OC(C)(C)C SVSSZFBZFUSINI-HTQZYQBOSA-N 0.000 description 2
• JMGZPXDZQWTPNB-ATTQYFOMSA-N 2-[4-methyl-3-[4-[[(2S,3R)-3-phenylmethoxypyrrolidin-2-yl]methoxy]cyclohexen-1-yl]pyridin-2-yl]oxyacetic acid Chemical compound CC1=C(C(CC2)=CCC2OC[C@@H]2NCC[C@H]2OCC2=CC=CC=C2)C(OCC(O)=O)=NC=C1 JMGZPXDZQWTPNB-ATTQYFOMSA-N 0.000 description 2
• VMBBWQWAGPEJOA-MNNMKWMVSA-N 2-[6-methyl-5-[4-[[(2R,3S)-3-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-2-yl]methoxy]cyclohexen-1-yl]pyrimidin-4-yl]oxyacetic acid Chemical compound CC(C)(C)OC(N[C@@H]1[C@H](COC(CC2)CC=C2C2=C(C)N=CN=C2OCC(O)=O)NCCC1)=O VMBBWQWAGPEJOA-MNNMKWMVSA-N 0.000 description 2
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
• FVIZOBDAEIFYGH-UHFFFAOYSA-N 3-bromo-2-(bromomethyl)pyridine Chemical compound BrCC1=NC=CC=C1Br FVIZOBDAEIFYGH-UHFFFAOYSA-N 0.000 description 2
• SXBCGEAJVXDYBL-UHFFFAOYSA-N 3-bromo-2-fluoro-4-methylpyridine Chemical compound CC1=CC=NC(F)=C1Br SXBCGEAJVXDYBL-UHFFFAOYSA-N 0.000 description 2
• 206010065687 Bone loss Diseases 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• AEQFTBPSKQJVSU-WIXBZOCESA-N C(C)(C)(C)OC(=O)N[C@@H]1[C@@H](N(CCC1)C(=O)OCC1=CC=CC=C1)COC1CC=C(CC1)B1OC(C(O1)(C)C)(C)C Chemical compound C(C)(C)(C)OC(=O)N[C@@H]1[C@@H](N(CCC1)C(=O)OCC1=CC=CC=C1)COC1CC=C(CC1)B1OC(C(O1)(C)C)(C)C AEQFTBPSKQJVSU-WIXBZOCESA-N 0.000 description 2
• OHTSTHUOXQFACY-VXKWHMMOSA-N C(C)(C)(C)OC(=O)N[C@@H]1[C@@H](N(CCC1)C(=O)OCC1=CC=CC=C1)COC1CCC(CC1)=O Chemical compound C(C)(C)(C)OC(=O)N[C@@H]1[C@@H](N(CCC1)C(=O)OCC1=CC=CC=C1)COC1CCC(CC1)=O OHTSTHUOXQFACY-VXKWHMMOSA-N 0.000 description 2
• KMHKVDDPQAXXLI-RBUKOAKNSA-N C(C1=CC=CC=C1)O[C@H]1[C@@H](N(CC1)C(=O)OCC1=CC=CC=C1)C=O Chemical compound C(C1=CC=CC=C1)O[C@H]1[C@@H](N(CC1)C(=O)OCC1=CC=CC=C1)C=O KMHKVDDPQAXXLI-RBUKOAKNSA-N 0.000 description 2
• NMATXWDBAQGTOV-RBUKOAKNSA-N C(C1=CC=CC=C1)O[C@H]1[C@@H](N(CC1)C(=O)OCC1=CC=CC=C1)CO Chemical compound C(C1=CC=CC=C1)O[C@H]1[C@@H](N(CC1)C(=O)OCC1=CC=CC=C1)CO NMATXWDBAQGTOV-RBUKOAKNSA-N 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 206010012218 Delirium Diseases 0.000 description 2
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
• 208000012661 Dyskinesia Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 208000023105 Huntington disease Diseases 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 206010053712 Hypersomnia-bulimia syndrome Diseases 0.000 description 2
• 208000001456 Jet Lag Syndrome Diseases 0.000 description 2
• 201000008178 Kleine-Levin syndrome Diseases 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
• 208000007101 Muscle Cramp Diseases 0.000 description 2
• 208000002033 Myoclonus Diseases 0.000 description 2
• JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
• 208000035959 Narcolepsy type 1 Diseases 0.000 description 2
• 208000033409 Narcolepsy type 2 Diseases 0.000 description 2
• 208000028389 Nerve injury Diseases 0.000 description 2
• 208000025966 Neurological disease Diseases 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 206010062519 Poor quality sleep Diseases 0.000 description 2
• 201000010769 Prader-Willi syndrome Diseases 0.000 description 2
• 208000028017 Psychotic disease Diseases 0.000 description 2
• 208000017442 Retinal disease Diseases 0.000 description 2
• 206010038923 Retinopathy Diseases 0.000 description 2
• 206010040047 Sepsis Diseases 0.000 description 2
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
• 208000005392 Spasm Diseases 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 206010047700 Vomiting Diseases 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 125000003342 alkenyl group Chemical group 0.000 description 2
• 125000003545 alkoxy group Chemical group 0.000 description 2
• 125000000304 alkynyl group Chemical group 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 235000019270 ammonium chloride Nutrition 0.000 description 2
• VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
• MJSHDCCLFGOEIK-UHFFFAOYSA-N benzyl (2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)OCC1=CC=CC=C1 MJSHDCCLFGOEIK-UHFFFAOYSA-N 0.000 description 2
• VGVHIFHEEFKWDA-UHFFFAOYSA-N benzyl 2-(3-bromo-4-methylpyridin-2-yl)oxyacetate Chemical compound CC(C=CN=C1OCC(OCC2=CC=CC=C2)=O)=C1Br VGVHIFHEEFKWDA-UHFFFAOYSA-N 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 229910000024 caesium carbonate Inorganic materials 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 206010008118 cerebral infarction Diseases 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 201000001883 cholelithiasis Diseases 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 238000001803 electron scattering Methods 0.000 description 2
• 206010014599 encephalitis Diseases 0.000 description 2
• KVXLZFNWVRPXNQ-UHFFFAOYSA-N ethyl 2-(3-bromo-4-methylpyridin-2-yl)oxyacetate Chemical compound CCOC(COC1=NC=CC(C)=C1Br)=O KVXLZFNWVRPXNQ-UHFFFAOYSA-N 0.000 description 2
• NHTBOQXMYIPSBP-UHFFFAOYSA-N ethyl 2-(5-bromo-6-methylpyrimidin-4-yl)oxyacetate Chemical compound CCOC(COC1=NC=NC(C)=C1Br)=O NHTBOQXMYIPSBP-UHFFFAOYSA-N 0.000 description 2
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 239000007897 gelcap Substances 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 230000002440 hepatic effect Effects 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 239000003701 inert diluent Substances 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 229910052500 inorganic mineral Inorganic materials 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 239000007937 lozenge Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 208000024714 major depressive disease Diseases 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• FPZOEPPXPLBIAN-TYSVMGFPSA-N methyl (2R,3R)-3-hydroxypyrrolidine-2-carboxylate hydrochloride Chemical compound Cl.COC(=O)[C@@H]1NCC[C@H]1O FPZOEPPXPLBIAN-TYSVMGFPSA-N 0.000 description 2
• 235000010755 mineral Nutrition 0.000 description 2
• 239000011707 mineral Substances 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• 230000002151 myoclonic effect Effects 0.000 description 2
• XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 2
• 208000004461 narcolepsy 1 Diseases 0.000 description 2
• 230000008764 nerve damage Effects 0.000 description 2
• 230000000926 neurological effect Effects 0.000 description 2
• 125000004433 nitrogen atom Chemical group N* 0.000 description 2
• 238000011275 oncology therapy Methods 0.000 description 2
• OFNHNCAUVYOTPM-IIIOAANCSA-N orexin-a Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N2)[C@@H](C)O)=O)CSSC1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CNC=N1 OFNHNCAUVYOTPM-IIIOAANCSA-N 0.000 description 2
• OHOWSYIKESXDMN-WMQZXSDYSA-N orexin-b Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)C1=CNC=N1 OHOWSYIKESXDMN-WMQZXSDYSA-N 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 208000019906 panic disease Diseases 0.000 description 2
• 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 description 2
• 238000012877 positron emission topography Methods 0.000 description 2
• 208000028173 post-traumatic stress disease Diseases 0.000 description 2
• 235000011056 potassium acetate Nutrition 0.000 description 2
• NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
• 238000001953 recrystallisation Methods 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 239000012312 sodium hydride Substances 0.000 description 2
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 238000013222 sprague-dawley male rat Methods 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
• ROCMSZSNVCNZSS-UHFFFAOYSA-N tert-butyl N-[2-(1,4-dioxaspiro[4.5]decan-8-yloxymethyl)piperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(NC1C(COC(CC2)CCC22OCCO2)NCCC1)=O ROCMSZSNVCNZSS-UHFFFAOYSA-N 0.000 description 2
• NIXJAXZTNDDEHX-UHFFFAOYSA-N tert-butyl N-[2-(1,4-dioxaspiro[4.5]decan-8-yloxymethyl)pyridin-3-yl]carbamate Chemical compound CC(C)(C)OC(NC1=CC=CN=C1COC(CC1)CCC11OCCO1)=O NIXJAXZTNDDEHX-UHFFFAOYSA-N 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
• UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
• FCFWEOGTZZPCTO-MRVPVSSYSA-N (2r)-3,6-dimethoxy-2-propan-2-yl-2,5-dihydropyrazine Chemical compound COC1=N[C@H](C(C)C)C(OC)=NC1 FCFWEOGTZZPCTO-MRVPVSSYSA-N 0.000 description 1
• JLDHXHPQMBNKMC-RNFRBKRXSA-N (2r,3r)-3-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](O)[C@@H]1C(O)=O JLDHXHPQMBNKMC-RNFRBKRXSA-N 0.000 description 1
• KZEDPVFJLQLDIZ-UHFFFAOYSA-N (5-diphenylphosphanyl-9,9-dimethylxanthen-4-yl)-diphenylphosphane Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1.C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZEDPVFJLQLDIZ-UHFFFAOYSA-N 0.000 description 1
• DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
• 125000006408 1,3-thiazinanyl group Chemical group 0.000 description 1
• HKQTYQDNCKMNHZ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-ol Chemical compound C1CC(O)CCC21OCCO2 HKQTYQDNCKMNHZ-UHFFFAOYSA-N 0.000 description 1
• FBYSMQIORYYPOI-VXGBXAGGSA-N 1-O-benzyl 2-O-methyl (2R,3R)-3-hydroxypyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)[C@H]1[C@H](O)CCN1C(=O)OCc1ccccc1 FBYSMQIORYYPOI-VXGBXAGGSA-N 0.000 description 1
• MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
• FKVXIRJVRIOURS-UHFFFAOYSA-N 1-chloropyrrolidine-2,5-dione Chemical compound ClN1C(=O)CCC1=O.ClN1C(=O)CCC1=O FKVXIRJVRIOURS-UHFFFAOYSA-N 0.000 description 1
• CWRFSVAKVCSOPI-UHFFFAOYSA-N 1-o-tert-butyl 3-o-ethyl 4-oxopyrrolidine-1,3-dicarboxylate Chemical compound CCOC(=O)C1CN(C(=O)OC(C)(C)C)CC1=O CWRFSVAKVCSOPI-UHFFFAOYSA-N 0.000 description 1
• ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
• BNDCYQXUFIHUHS-UHFFFAOYSA-N 2,5-dihydropyrazine Chemical compound C1C=NCC=N1 BNDCYQXUFIHUHS-UHFFFAOYSA-N 0.000 description 1
• DMYZZZCPJOWSNT-UHFFFAOYSA-N 2-(3-fluorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=CC(F)=C1 DMYZZZCPJOWSNT-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• LIGLFMMBXCFHQJ-UHFFFAOYSA-N 2-[4-(chloromethoxy)cyclohexyl]-1-methyl-3-phenylmethoxybenzene Chemical compound CC1=CC=CC(OCC2=CC=CC=C2)=C1C(CC1)CCC1OCCl LIGLFMMBXCFHQJ-UHFFFAOYSA-N 0.000 description 1
• OVLJYZJSUSABQM-YPJRHXLCSA-N 2-[4-methyl-3-[4-[[(2R,3S)-3-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-2-yl]methoxy]cyclohexen-1-yl]pyridin-2-yl]oxyacetic acid Chemical compound CC(C)(C)OC(N[C@@H]1[C@H](COC(CC2)CC=C2C2=C(C)C=CN=C2OCC(O)=O)NCCC1)=O OVLJYZJSUSABQM-YPJRHXLCSA-N 0.000 description 1
• SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
• 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
• IXLVUUFUDRJUSL-RPBOFIJWSA-N 5-[[4-(3-acetamidophenyl)phenyl]methyl]-n-[(1s,2r)-2-phenylcyclopropyl]-1,3-oxazole-4-carboxamide Chemical compound CC(=O)NC1=CC=CC(C=2C=CC(CC3=C(N=CO3)C(=O)N[C@@H]3[C@H](C3)C=3C=CC=CC=3)=CC=2)=C1 IXLVUUFUDRJUSL-RPBOFIJWSA-N 0.000 description 1
• COSNNPGRFRGVPC-UHFFFAOYSA-N 5-bromo-4-chloro-6-methylpyrimidine Chemical compound CC1=NC=NC(Cl)=C1Br COSNNPGRFRGVPC-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 208000004611 Abdominal Obesity Diseases 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 208000008811 Agoraphobia Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000031091 Amnestic disease Diseases 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
• 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
• 208000008035 Back Pain Diseases 0.000 description 1
• 208000020925 Bipolar disease Diseases 0.000 description 1
• 206010006002 Bone pain Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• LPZSLGKLXFGYGN-UHFFFAOYSA-N BrC1=C(OCC(=O)OCC2=CC=CC=C2)C=CC=C1F Chemical compound BrC1=C(OCC(=O)OCC2=CC=CC=C2)C=CC=C1F LPZSLGKLXFGYGN-UHFFFAOYSA-N 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 206010052346 Brain contusion Diseases 0.000 description 1
• 206010048962 Brain oedema Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• ZLBDSZNVMHRAPS-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1C(NCCC1)COC1CC=C(CC1)C1=C(OCC(=O)O)C=CC=C1F Chemical compound C(C)(C)(C)OC(=O)NC1C(NCCC1)COC1CC=C(CC1)C1=C(OCC(=O)O)C=CC=C1F ZLBDSZNVMHRAPS-UHFFFAOYSA-N 0.000 description 1
• GCWVXNKCRFHILN-GFUWAVFVSA-N C(C)(C)(C)OC(=O)N[C@@H]1[C@@H](N(CCC1)C(=O)OCC1=CC=CC=C1)COC1CC=C(CC1)OS(=O)(=O)C(F)(F)F Chemical compound C(C)(C)(C)OC(=O)N[C@@H]1[C@@H](N(CCC1)C(=O)OCC1=CC=CC=C1)COC1CC=C(CC1)OS(=O)(=O)C(F)(F)F GCWVXNKCRFHILN-GFUWAVFVSA-N 0.000 description 1
• BIJFOGGRRLIURY-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(COC1=C(C(=CC=C1)F)C1=CCC(CC1)OCC1N(CCCC1NC(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1)=O Chemical compound C(C1=CC=CC=C1)OC(COC1=C(C(=CC=C1)F)C1=CCC(CC1)OCC1N(CCCC1NC(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1)=O BIJFOGGRRLIURY-UHFFFAOYSA-N 0.000 description 1
• DGRFPXPOAQZVGO-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=C(C=CC=C1)C1CCC(CC1)=O Chemical compound C(C1=CC=CC=C1)OC1=C(C=CC=C1)C1CCC(CC1)=O DGRFPXPOAQZVGO-UHFFFAOYSA-N 0.000 description 1
• WTERZKKCZFAOTD-RTBURBONSA-N C(C1=CC=CC=C1)O[C@H]1[C@@H](N(CC1)C(=O)OCC1=CC=CC=C1)C(=O)OC Chemical compound C(C1=CC=CC=C1)O[C@H]1[C@@H](N(CC1)C(=O)OCC1=CC=CC=C1)C(=O)OC WTERZKKCZFAOTD-RTBURBONSA-N 0.000 description 1
• ICUNXLSHMCEIOW-CVWZLOPKSA-N C(C1=CC=CC=C1)O[C@H]1[C@@H](N(CC1)C(=O)OCC1=CC=CC=C1)COC1CC=C(CC1)B1OC(C(O1)(C)C)(C)C Chemical compound C(C1=CC=CC=C1)O[C@H]1[C@@H](N(CC1)C(=O)OCC1=CC=CC=C1)COC1CC=C(CC1)B1OC(C(O1)(C)C)(C)C ICUNXLSHMCEIOW-CVWZLOPKSA-N 0.000 description 1
• 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
• 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
• MQCBRMREMNGMNK-UHFFFAOYSA-N CN1C(N(CCC1)C)=O.CN1C(N(CCC1)C)=O Chemical group CN1C(N(CCC1)C)=O.CN1C(N(CCC1)C)=O MQCBRMREMNGMNK-UHFFFAOYSA-N 0.000 description 1
• VOSAWOSMGPKQEQ-OALUTQOASA-N CS(=O)(=O)N[C@@H]1[C@@H](N(CC1)C(C(C)(C)O)=O)CC=1C(=C(C=CC=1)C1=CC(=CC(=C1)F)F)F Chemical group CS(=O)(=O)N[C@@H]1[C@@H](N(CC1)C(C(C)(C)O)=O)CC=1C(=C(C=CC=1)C1=CC(=CC(=C1)F)F)F VOSAWOSMGPKQEQ-OALUTQOASA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 206010065941 Central obesity Diseases 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
• 208000017164 Chronobiology disease Diseases 0.000 description 1
• 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
• 208000028698 Cognitive impairment Diseases 0.000 description 1
• 206010009866 Cold sweat Diseases 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 229940126062 Compound A Drugs 0.000 description 1
• 208000032170 Congenital Abnormalities Diseases 0.000 description 1
• 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• 208000024254 Delusional disease Diseases 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• 208000014094 Dystonic disease Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 241001125671 Eretmochelys imbricata Species 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 208000010235 Food Addiction Diseases 0.000 description 1
• 201000001498 Froelich syndrome Diseases 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 230000005526 G1 to G0 transition Effects 0.000 description 1
• 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000011688 Generalised anxiety disease Diseases 0.000 description 1
• 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 206010056438 Growth hormone deficiency Diseases 0.000 description 1
• 208000016905 Hashimoto encephalopathy Diseases 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
• 206010020112 Hirsutism Diseases 0.000 description 1
• 101100188801 Homo sapiens HCRT gene Proteins 0.000 description 1
• 101001098357 Homo sapiens Orexin receptor type 2 Proteins 0.000 description 1
• 208000033830 Hot Flashes Diseases 0.000 description 1
• 206010060800 Hot flush Diseases 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 208000031226 Hyperlipidaemia Diseases 0.000 description 1
• 206010020710 Hyperphagia Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 201000001431 Hyperuricemia Diseases 0.000 description 1
• 206010021133 Hypoventilation Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
• 208000009829 Lewy Body Disease Diseases 0.000 description 1
• 201000002832 Lewy body dementia Diseases 0.000 description 1
• 229910010082 LiAlH Inorganic materials 0.000 description 1
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000025972 Maternal Obesity Diseases 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 201000002983 Mobius syndrome Diseases 0.000 description 1
• 208000034167 Moebius syndrome Diseases 0.000 description 1
• 208000001089 Multiple system atrophy Diseases 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
• 102000003797 Neuropeptides Human genes 0.000 description 1
• 108090000189 Neuropeptides Proteins 0.000 description 1
• 208000010577 Niemann-Pick disease type C Diseases 0.000 description 1
• 208000004166 Obesity Hypoventilation Syndrome Diseases 0.000 description 1
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 206010033664 Panic attack Diseases 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000007683 Pediatric Obesity Diseases 0.000 description 1
• 102000015439 Phospholipases Human genes 0.000 description 1
• 108010064785 Phospholipases Proteins 0.000 description 1
• 206010035004 Pickwickian syndrome Diseases 0.000 description 1
• 206010036049 Polycystic ovaries Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
• 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 208000005793 Restless legs syndrome Diseases 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• 208000000810 Separation Anxiety Diseases 0.000 description 1
• 208000020221 Short stature Diseases 0.000 description 1
• BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• 208000032140 Sleepiness Diseases 0.000 description 1
• 206010041250 Social phobia Diseases 0.000 description 1
• 206010041347 Somnambulism Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 201000008736 Systemic mastocytosis Diseases 0.000 description 1
• 208000009205 Tinnitus Diseases 0.000 description 1
• 208000000323 Tourette Syndrome Diseases 0.000 description 1
• 208000016620 Tourette disease Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• 208000026928 Turner syndrome Diseases 0.000 description 1
• 208000007930 Type C Niemann-Pick Disease Diseases 0.000 description 1
• 101150049278 US20 gene Proteins 0.000 description 1
• 208000003443 Unconsciousness Diseases 0.000 description 1
• 206010046543 Urinary incontinence Diseases 0.000 description 1
• PCBOWMZAEDDKNH-HOTGVXAUSA-N [4-(trifluoromethoxy)phenyl]methyl (3as,6as)-2-(3-fluoro-4-sulfamoylbenzoyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1=C(F)C(S(=O)(=O)N)=CC=C1C(=O)N1C[C@H]2CN(C(=O)OCC=3C=CC(OC(F)(F)F)=CC=3)C[C@@H]2C1 PCBOWMZAEDDKNH-HOTGVXAUSA-N 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 108010076089 accutase Proteins 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 230000009056 active transport Effects 0.000 description 1
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 208000026345 acute stress disease Diseases 0.000 description 1
• YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 230000007000 age related cognitive decline Effects 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 208000008784 apnea Diseases 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 230000006793 arrhythmia Effects 0.000 description 1
• 206010003119 arrhythmia Diseases 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 125000004069 aziridinyl group Chemical group 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• OMUUDLSEEWAUBA-FHODTQPZSA-N benzyl (2R,3S)-2-[[4-[4-methyl-2-(2-oxo-2-phenylmethoxyethoxy)pyridin-3-yl]cyclohex-3-en-1-yl]oxymethyl]-3-[(2-methylpropan-2-yl)oxycarbonylamino]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(N[C@@H](CCC1)[C@H](COC(CC2)CC=C2C2=C(C)C=CN=C2OCC(OCC2=CC=CC=C2)=O)N1C(OCC1=CC=CC=C1)=O)=O OMUUDLSEEWAUBA-FHODTQPZSA-N 0.000 description 1
• VPYJBEIOKFRWQZ-UHFFFAOYSA-N benzyl 2-hydroxyacetate Chemical compound OCC(=O)OCC1=CC=CC=C1 VPYJBEIOKFRWQZ-UHFFFAOYSA-N 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 230000002457 bidirectional effect Effects 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 208000028683 bipolar I disease Diseases 0.000 description 1
• 208000022257 bipolar II disease Diseases 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 208000006752 brain edema Diseases 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 150000001722 carbon compounds Chemical class 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
• 229960003184 carprofen Drugs 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 210000001638 cerebellum Anatomy 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 208000026106 cerebrovascular disease Diseases 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 208000012601 choreatic disease Diseases 0.000 description 1
• 238000013375 chromatographic separation Methods 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000002967 competitive immunoassay Methods 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000013058 crude material Substances 0.000 description 1
• 150000003950 cyclic amides Chemical class 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 208000026725 cyclothymic disease Diseases 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 239000011903 deuterated solvents‎ Substances 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• YKNYFZIYLYVWLF-UHFFFAOYSA-N dicyclohexyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical group CC(C)c1cc(C(C)C)c(c(c1)C(C)C)-c1ccccc1P(C1CCCCC1)C1CCCCC1.CC(C)c1cc(C(C)C)c(c(c1)C(C)C)-c1ccccc1P(C1CCCCC1)C1CCCCC1 YKNYFZIYLYVWLF-UHFFFAOYSA-N 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• 235000014632 disordered eating Nutrition 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 229960003722 doxycycline Drugs 0.000 description 1
• XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 206010013663 drug dependence Diseases 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 208000024732 dysthymic disease Diseases 0.000 description 1
• 208000010118 dystonia Diseases 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000019439 energy homeostasis Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• UPNYCKWBUGMZQF-NCPLZGKYSA-N ethyl 2-[4-methyl-3-[4-[[(2S,3R)-3-phenylmethoxypyrrolidin-2-yl]methoxy]cyclohexen-1-yl]pyridin-2-yl]oxyacetate Chemical compound CCOC(COC1=NC=CC(C)=C1C(CC1)=CCC1OC[C@@H]1NCC[C@H]1OCC1=CC=CC=C1)=O UPNYCKWBUGMZQF-NCPLZGKYSA-N 0.000 description 1
• ZANNOFHADGWOLI-UHFFFAOYSA-N ethyl 2-hydroxyacetate Chemical compound CCOC(=O)CO ZANNOFHADGWOLI-UHFFFAOYSA-N 0.000 description 1
• PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 231100000040 eye damage Toxicity 0.000 description 1
• 201000005577 familial hyperlipidemia Diseases 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 230000035558 fertility Effects 0.000 description 1
• 231100000502 fertility decrease Toxicity 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 238000004508 fractional distillation Methods 0.000 description 1
• 210000001652 frontal lobe Anatomy 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 208000020694 gallbladder disease Diseases 0.000 description 1
• 208000001130 gallstones Diseases 0.000 description 1
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 208000029364 generalized anxiety disease Diseases 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 230000002710 gonadal effect Effects 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 230000010370 hearing loss Effects 0.000 description 1
• 231100000888 hearing loss Toxicity 0.000 description 1
• 208000016354 hearing loss disease Diseases 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000044551 human HCRTR2 Human genes 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 125000001183 hydrocarbyl group Chemical group 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• 230000002267 hypothalamic effect Effects 0.000 description 1
• 210000003016 hypothalamus Anatomy 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 230000000266 injurious effect Effects 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 229960001632 labetalol Drugs 0.000 description 1
• 150000003951 lactams Chemical class 0.000 description 1
• 150000002596 lactones Chemical class 0.000 description 1
• 208000010325 limbic encephalitis Diseases 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• PESIDIPGHQPGJX-UHFFFAOYSA-N lithium;2,3,4-trimethylpentan-3-ylazanide Chemical compound [Li+].CC(C)C(C)([NH-])C(C)C PESIDIPGHQPGJX-UHFFFAOYSA-N 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 208000008585 mastocytosis Diseases 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
• UXZAJSZFFARTEI-GUMHCPJTSA-N methyl (2R,3S)-3-(methanesulfonamido)-2-[(4-phenylcyclohexyl)oxymethyl]piperidine-1-carboxylate Chemical compound COC(=O)N1CCC[C@H](NS(C)(=O)=O)[C@@H]1COC1CCC(CC1)c1ccccc1 UXZAJSZFFARTEI-GUMHCPJTSA-N 0.000 description 1
• YNQNTUVMQPQFEW-UHFFFAOYSA-N methyl 2-hydroxyacetate;sodium Chemical compound [Na].COC(=O)CO YNQNTUVMQPQFEW-UHFFFAOYSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 230000008450 motivation Effects 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 201000006938 muscular dystrophy Diseases 0.000 description 1
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
• PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
• WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 208000023046 narcolepsy-cataplexy syndrome Diseases 0.000 description 1
• 210000004237 neck muscle Anatomy 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 208000004296 neuralgia Diseases 0.000 description 1
• 208000008795 neuromyelitis optica Diseases 0.000 description 1
• 208000021722 neuropathic pain Diseases 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 230000000422 nocturnal effect Effects 0.000 description 1
• 208000005346 nocturnal enuresis Diseases 0.000 description 1
• 230000000414 obstructive effect Effects 0.000 description 1
• 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
• 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
• 235000014593 oils and fats Nutrition 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 238000006053 organic reaction Methods 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 230000003534 oscillatory effect Effects 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 235000020830 overeating Nutrition 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000000160 oxazolidinyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 208000002851 paranoid schizophrenia Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000001936 parietal effect Effects 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 208000033300 perinatal asphyxia Diseases 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 208000019899 phobic disease Diseases 0.000 description 1
• 239000008055 phosphate buffer solution Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 238000012805 post-processing Methods 0.000 description 1
• 239000011698 potassium fluoride Substances 0.000 description 1
• 235000003270 potassium fluoride Nutrition 0.000 description 1
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000002360 prefrontal effect Effects 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 208000023504 respiratory system disease Diseases 0.000 description 1
• 230000033764 rhythmic process Effects 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• 208000022610 schizoaffective disease Diseases 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 230000020341 sensory perception of pain Effects 0.000 description 1
• 208000025874 separation anxiety disease Diseases 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000036299 sexual function Effects 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229910000077 silane Inorganic materials 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 230000003860 sleep quality Effects 0.000 description 1
• 230000037321 sleepiness Effects 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 238000012453 sprague-dawley rat model Methods 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 208000011117 substance-related disease Diseases 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000000153 supplemental effect Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 238000004885 tandem mass spectrometry Methods 0.000 description 1
• YKEXRCCLYZWXKA-UHFFFAOYSA-N tert-butyl 2-[[4-(2-methyl-6-phenylmethoxyphenyl)cyclohexyl]oxymethyl]-3-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(N(CC1)C(COC(CC2)CCC2C(C(C)=CC=C2)=C2OCC2=CC=CC=C2)C1=O)=O YKEXRCCLYZWXKA-UHFFFAOYSA-N 0.000 description 1
• BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
• GMRIOAVKKGNMMV-UHFFFAOYSA-N tetrabutylazanium;azide Chemical compound [N-]=[N+]=[N-].CCCC[N+](CCCC)(CCCC)CCCC GMRIOAVKKGNMMV-UHFFFAOYSA-N 0.000 description 1
• CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 231100000886 tinnitus Toxicity 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 208000004371 toothache Diseases 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
• GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 1
• 206010044652 trigeminal neuralgia Diseases 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1